このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Iovance Biotherapeutics 将来の成長

Future 基準チェック /56

Iovance Biotherapeuticsは、64.9%と46.2%でそれぞれ年率64.9%で利益と収益が成長すると予測される一方、EPSはgrowで67.8%年率。

主要情報

64.5%

収益成長率

67.5%

EPS成長率

Biotechs 収益成長	30.2%
収益成長率	46.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	20 Jun 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

DB:2LB - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	694	-38	69	169	7
12/31/2025	391	-231	-151	-82	12
12/31/2024	150	-355	-272	-221	13
3/31/2024	2	-450	-405	-384	N/A
12/31/2023	1	-444	-384	-362	N/A
9/30/2023	1	-433	-377	-356	N/A
6/30/2023	0	-419	-355	-335	N/A
3/31/2023	N/A	-412	-333	-319	N/A
12/31/2022	N/A	-396	-313	-293	N/A
9/30/2022	N/A	-390	-294	-269	N/A
6/30/2022	N/A	-376	-296	-263	N/A
3/31/2022	N/A	-358	-278	-239	N/A
12/31/2021	N/A	-342	-266	-228	N/A
9/30/2021	N/A	-311	-290	-237	N/A
6/30/2021	N/A	-284	-281	-220	N/A
3/31/2021	N/A	-265	-259	-202	N/A
12/31/2020	N/A	-260	-252	-205	N/A
9/30/2020	N/A	-255	-223	-196	N/A
6/30/2020	N/A	-246	-208	-198	N/A
3/31/2020	N/A	-230	-202	-195	N/A
12/31/2019	N/A	-198	-166	-159	N/A
9/30/2019	N/A	-167	-140	-137	N/A
6/30/2019	N/A	-151	-125	-122	N/A
3/31/2019	N/A	-134	-114	-112	N/A
12/31/2018	N/A	-124	-102	-101	N/A
9/30/2018	N/A	-117	-92	-91	N/A
6/30/2018	N/A	-105	-85	-84	N/A
3/31/2018	N/A	-98	-78	-78	N/A
12/31/2017	N/A	-92	N/A	-79	N/A
9/30/2017	N/A	-82	N/A	-70	N/A
6/30/2017	N/A	-128	N/A	-61	N/A
3/31/2017	N/A	-116	N/A	-47	N/A
12/31/2016	N/A	-102	N/A	-33	N/A
9/30/2016	N/A	-95	N/A	-27	N/A
6/30/2016	N/A	-34	N/A	-19	N/A
3/31/2016	N/A	-29	N/A	-19	N/A
12/31/2015	N/A	-28	N/A	-18	N/A
9/30/2015	N/A	-24	N/A	-15	N/A
6/30/2015	N/A	-19	N/A	-13	N/A
3/31/2015	N/A	-15	N/A	-10	N/A
12/31/2014	N/A	-12	N/A	-9	N/A
9/30/2014	N/A	-27	N/A	-8	N/A
6/30/2014	N/A	-34	N/A	-6	N/A
3/31/2014	N/A	-35	N/A	-6	N/A
12/31/2013	N/A	-34	N/A	-4	N/A
9/30/2013	N/A	-10	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 2LBは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 0.7% ) よりも高い成長率であると考えられます。

収益対市場: 2LB今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: 2LB今後 3 年以内に収益を上げることが予想されます。

収益対市場: 2LBの収益 ( 46.2% ) German市場 ( 5.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: 2LBの収益 ( 46.2% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 2LBの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Iovance Biotherapeutics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

Iovance Biotherapeutics, Inc. Elects Frederick G. Vogt as Director

No longer forecast to breakeven

New minor risk - Financial position

Iovance Biotherapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Iovance Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Iovance Biotherapeutics, Inc. Agrees to A Proposed Settlement

Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer

New minor risk - Profitability

Iovance Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $210.5781 million.

Iovance Biotherapeutics, Inc.’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

New minor risk - Profitability

Iovance Biotherapeutics, Inc. Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

Iovance Biotherapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

New major risk - Financial position

Independent Director recently bought €25m worth of stock

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Updates

New minor risk - Financial position

Iovance Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Iovance Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces U.S. Food and Drug Administration Accepts the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Insufficient new directors

Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA) entered into a definitive agreement to acquire Worldwide rights of Proleukin of Clinigen Limited fo

Independent Director recently bought €58k worth of stock

Independent Director recently bought €62m worth of stock

Independent Director recently bought €60k worth of stock

Iovance Biotherapeutics, Inc. Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (Sitc) Annual Meeting

Iovance Biotherapeutics, Inc. Announces Updated Clinical Data for Lifileucel in Advanced Melanoma At Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Iovance Biotherapeutics, Inc. Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte Therapy

Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 1000 Dynamic Index

Iovance Biotherapeutics, Inc. Appoints Wendy L. Dixon to Board of Directors

Independent Director recently bought €6.2m worth of stock

Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc. Announces Regulatory and Clinical Updates for Lifileucel in Melanoma

No longer forecast to breakeven

Iovance Biotherapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Iovance Biotherapeutics, Inc. Initiates Clinical Supply of Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy Manufactured At Iovance Cell Therapy Center (iCTC)

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer

Iovance Biotherapeutics, Inc. Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting

Iovance Biotherapeutics, Inc. Provides Regulatory Update for Lifileucel Potency Assays

Iovance Biotherapeutics, Inc. Appoints Igor Bilinsky as Chief Operating Officer

Iovance Biotherapeutics, Inc. Announces Board Changes

New 90-day low: €29.83

Iovance Biotherapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Iovance Biotherapeutics, Inc. Enters into a Lease Agreement with ARE-San Francisco No. 63, LLC

New 90-day high: €42.20

New 90-day high: €41.84

Iovance Biotherapeutics Appoints Jean-Marc Bellemin as Chief Financial Officer

New 90-day high: €35.36

Iovance Biotherapeutics, Inc. Presents Clinical Data in Head and Neck Cancer At Society for Immunotherapy of Cancer (SITC) Annual Meeting

New 90-day high: €33.85

Iovance Biotherapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020

New 90-day high: €32.19

Iovance Biotherapeutics, Inc. Announces That Copy of an Abstract Submitted At Society for Immunotherapy in Cancer Annual Meeting Published by SITC

Iovance Biotherapeutics Provides Update for Lifileucel in Metastatic Melanoma

Iovance Biotherapeutics, Inc. Announces First Patient Dosed in Cohort 4 of Pivotal InnovaTIL-01 Study of Lifileucel in Metastatic Melanoma

New 90-day high - €28.48

New 90-day low - €23.78

Iovance Biotherapeutics, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Iovance Biotherapeutics, Inc.(NasdaqGM:IOVA) dropped from Russell 2000 Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘